Biotech | April 03, 2022
USFDA approves Yescarta as first CAR T-cell therapy for Lymphoma
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
It is one of the 15 medical device manufacturers approved under the government’s PLI scheme
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
The plant is scheduled to come on stream in September 2024
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".
Technology Development Board supports commercialisation of Metal Injection Molding of implants
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Subscribe To Our Newsletter & Stay Updated
